Altimmune, Inc.: shareholders and insiders

ALTNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.33

November 20, 2026Market cap $259M

What Ploutos Investor adds for Altimmune

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 12 fiscal years, from 2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Nov 18, 2026, from their own Form 4 filings.

14 Form 4s

Bought on the market

$466.6K

7 people

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $361.7K by 6 people·no sales

  • 2025: bought $104.9K by 3 people, no sales
  • 2026: bought $361.7K by 6 people, no sales
  • Nov 18, 2026Richard Thomas MenziusoPrincipal Accounting Officer
    Kind
  • Nov 13, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Nov 13, 2026Wayne PisanoDirector
    Kind
  • Nov 13, 2026Jerome Benedict DursoPresident and CEO
    Kind
  • Nov 11, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Nov 11, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Oct 1, 2026Christophe Arbet-EngelsChief Medical Officer
    Kind
  • Oct 1, 2026Christophe Arbet-EngelsChief Medical Officer
    Kind
  • Oct 1, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Oct 1, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Sep 16, 2026Linda M RichardsonChief Commercial Officer
    Kind
  • Sep 16, 2026Linda M RichardsonChief Commercial Officer
    Kind
  • Aug 13, 2026Jerome Benedict DursoPresident and CEO
    Kind
  • Jul 31, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Jul 31, 2026M Scot RobertsChief Scientific Officer
    Kind
  • Apr 6, 2026John Gill
    Kind
  • Apr 1, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Apr 1, 2026Jerome Benedict DursoPresident and CEO
    Kind
  • Mar 6, 2026Gregory L WeaverChief Financial Officer
    Kind
  • Mar 6, 2026Jerome Benedict DursoPresident and CEO
    Kind
  • Jan 8, 2026Wayne Pisano
    Kind
  • Jan 5, 2026Catherine A. Sohn
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Aug 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by ALT's officers and directors from 2007 up to November 21, 2025, 19 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

5 Holders over 5%Nov 10, 2026 Latest filing
  • Deep Track Capital, LPwith 3 more persons
    Share of class9.99%
  • TCG Crossover GP II, LLCwith 4 more persons
    Share of class9.80%
  • BlackRock, Inc.
    Share of class7.60%
  • Viking Global Investorswith 9 more persons
    Share of class6.70%
  • RA Capital Management, L.P.with 3 more persons
    Share of class6.50%
Fell to 5% or less (4)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • State Street4.30%Nov 10, 202613G
  • Tang Capital Management0.30%May 15, 202613G/A
  • The Vanguard Group0.00%Mar 26, 202613G/A
  • Ameriprise Financial, Inc.1.90%May 15, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Viking Global (Halvorsen)
    In the quarter
  • Point72 (Cohen)
    In the quarter+200%
  • Millennium Mgmt (Englander)
    In the quarter+16%
  • Citadel Advisors (Griffin)
    In the quarter-29%
  • D.E. Shaw
    In the quarter+185%
  • Renaissance Technologies
    In the quarter+51%
  • AQR Capital
    In the quarter-95%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 21.7% of its shares outstanding were held short, -8.3% since the report before.

Shares held short
42.23M
21.7%
Since the report before46.08M on Sep 30, 2026
-8.3%
10.4
4.05M
More days to cover thanof 4,578 US-listed companies with enough volume
92%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 6.86M
  • Nov 15, 2023: Shares held short 6.73M
  • Nov 30, 2023: Shares held short 6.45M
  • Dec 15, 2023: Shares held short 11.09M
  • Dec 29, 2023: Shares held short 9.44M
  • Jan 12, 2024: Shares held short 10.66M
  • Jan 31, 2024: Shares held short 10.01M
  • Feb 15, 2024: Shares held short 11.55M
  • Feb 29, 2024: Shares held short 10.81M
  • Mar 15, 2024: Shares held short 12.51M
  • Mar 28, 2024: Shares held short 17.73M
  • Apr 15, 2024: Shares held short 20.37M
  • Apr 30, 2024: Shares held short 22.31M
  • May 15, 2024: Shares held short 23.06M
  • May 31, 2024: Shares held short 23.47M
  • Jun 14, 2024: Shares held short 23.14M
  • Jun 28, 2024: Shares held short 22.24M
  • Jul 15, 2024: Shares held short 22.61M
  • Jul 31, 2024: Shares held short 22.24M
  • Aug 15, 2024: Shares held short 21.70M
  • Aug 30, 2024: Shares held short 22.00M
  • Sep 13, 2024: Shares held short 21.87M
  • Sep 30, 2024: Shares held short 22.40M
  • Oct 15, 2024: Shares held short 22.23M
  • Oct 31, 2024: Shares held short 22.94M
  • Nov 15, 2024: Shares held short 22.84M
  • Nov 29, 2024: Shares held short 23.43M
  • Dec 13, 2024: Shares held short 23.85M
  • Dec 31, 2024: Shares held short 23.69M
  • Jan 15, 2025: Shares held short 24.59M
  • Jan 31, 2025: Shares held short 23.32M
  • Feb 14, 2025: Shares held short 22.47M
  • Feb 28, 2025: Shares held short 21.67M
  • Mar 14, 2025: Shares held short 22.45M
  • Mar 31, 2025: Shares held short 21.82M
  • Apr 15, 2025: Shares held short 22.44M
  • Apr 30, 2025: Shares held short 22.58M
  • May 15, 2025: Shares held short 22.67M
  • May 30, 2025: Shares held short 21.98M
  • Jun 13, 2025: Shares held short 24.40M
  • Jun 30, 2025: Shares held short 31.18M
  • Jul 15, 2025: Shares held short 28.10M
  • Jul 31, 2025: Shares held short 25.76M
  • Aug 15, 2025: Shares held short 25.46M
  • Aug 29, 2025: Shares held short 26.77M
  • Sep 15, 2025: Shares held short 25.08M
  • Sep 30, 2025: Shares held short 26.19M
  • Oct 15, 2025: Shares held short 21.50M
  • Oct 31, 2025: Shares held short 21.78M
  • Nov 14, 2025: Shares held short 23.29M
  • Nov 28, 2025: Shares held short 23.16M
  • Dec 15, 2025: Shares held short 23.72M
  • Dec 31, 2025: Shares held short 25.81M
  • Jan 15, 2026: Shares held short 26.41M
  • Jan 30, 2026: Shares held short 24.16M
  • Feb 13, 2026: Shares held short 25.13M
  • Feb 27, 2026: Shares held short 25.50M
  • Mar 13, 2026: Shares held short 26.49M
  • Mar 31, 2026: Shares held short 29.25M
  • Apr 15, 2026: Shares held short 28.73M
  • Apr 30, 2026: Shares held short 35.45M
  • May 15, 2026: Shares held short 37.64M
  • May 29, 2026: Shares held short 39.12M
  • Jun 15, 2026: Shares held short 41.93M
  • Jun 30, 2026: Shares held short 47.63M
  • Jul 15, 2026: Shares held short 48.24M
  • Jul 31, 2026: Shares held short 51.94M
  • Aug 14, 2026: Shares held short 50.97M
  • Aug 31, 2026: Shares held short 49.71M
  • Sep 15, 2026: Shares held short 51.75M
  • Sep 30, 2026: Shares held short 46.08M
  • Oct 15, 2026: Shares held short 42.23M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading61.5% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 61.5% of the shares in the reported trades were short sales, against 50.2% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
61.5%
The 14 beforeOct 14, 2026 – Nov 2, 2026
50.2%
Change
+11.3 pts
Short sales a dayon average, of 2.55M shares
1.57M
More than atof 3,666 US-listed companies, same days
86%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 46.5%
  • Oct 15, 2026: Short sales 46.7%
  • Oct 16, 2026: Short sales 53.1%
  • Oct 19, 2026: Short sales 51.3%
  • Oct 20, 2026: Short sales 59%
  • Oct 21, 2026: Short sales 45.9%
  • Oct 22, 2026: Short sales 47.9%
  • Oct 23, 2026: Short sales 57.8%
  • Oct 26, 2026: Short sales 57%
  • Oct 27, 2026: Short sales 42.7%
  • Oct 28, 2026: Short sales 56%
  • Oct 29, 2026: Short sales 49.8%
  • Oct 30, 2026: Short sales 51.5%
  • Nov 2, 2026: Short sales 46.7%
  • Nov 3, 2026: Short sales 50.9%
  • Nov 4, 2026: Short sales 47.1%
  • Nov 5, 2026: Short sales 55.6%
  • Nov 6, 2026: Short sales 55%
  • Nov 9, 2026: Short sales 52.3%
  • Nov 10, 2026: Short sales 65.4%
  • Nov 11, 2026: Short sales 61%
  • Nov 12, 2026: Short sales 76.3%
  • Nov 13, 2026: Short sales 58.6%
  • Nov 16, 2026: Short sales 61.7%
  • Nov 17, 2026: Short sales 55.5%
  • Nov 18, 2026: Short sales 58.9%
  • Nov 19, 2026: Short sales 56%
  • Nov 20, 2026: Short sales 54.2%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

460.0K Insiders' shares0.35% Of the company
  • M Scot RobertsChief Scientific Officer
    Directly113.7K
  • Jerome Benedict DursoPresident and CEO
    Directly93.2K
  • Gregory L WeaverChief Financial Officer
    Directly63.0K
  • Wayne PisanoDirector
    Directly58.8K
  • David DrutzDirector
    Directly–
  • Christophe Arbet-EngelsChief Medical Officer
    Directly24.8K
  • John GillDirector
    Directly21.7K
  • Linda M RichardsonChief Commercial Officer
    Directly17.2K
  • Richard Thomas MenziusoPrincipal Accounting Officer
    Directly10.0K
  • Catherine A. SohnDirector
    Directly1,500
  • Diane JorkaskyDirector
    Directly527

A lower bound: it counts only the 11 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

17 ETFs holding it0.23% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.23%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.16%
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.13%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.04%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.04%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.03%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.02%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.02%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%

17 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

210 Managers, Q2 2026$461M Value of their positions
  • Q3 2025: Managers 158
  • Q4 2025: Managers 183
  • Q1 2026: Managers 175
  • Q2 2026: Managers 210

Institutional investors by quarter

The fund managers holding ALT, quarter by quarter, from Q1 2013 to Q2 2025, 34 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 210 managers held 152M shares, worth $461M. During the quarter 58 opened a position, 23 closed one, 84 added and 33 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+59%
  • Deep Track Capital
    In the quarter
  • State Street
    In the quarter+69%
  • TCG Crossover Management
    In the quarter
  • Vanguard Capital Management
    In the quarter+45%
  • Vanguard Portfolio Management
    In the quarter+36%
  • Marshall Wace
    In the quarter+70%
  • Viking Global (Halvorsen)
    In the quarter
  • Ra Capital Management
    In the quarter
  • Geode Capital Management
    In the quarter+61%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Altimmune's filings show?

Who buys and sells is one part of Altimmune's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ALT's shareholders

Didn't find what you were looking for?

Ask us
Have ALT's insiders bought or sold?

From Aug 3, 2026 to Nov 18, 2026 Altimmune's insiders bought $140.7K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.

Which well-known managers hold ALT?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was Viking Global (Halvorsen)'s, worth $19M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.